Publications by authors named "Amy C Porter"

Claim this Profile
Q
Qualification of translational safety biomarkers.
John-Michael Sauer, Amy C Porter

Exp Biol Med (Maywood)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.
Amy C Porter, Jiri Aubrecht, Chandler Birch, Jonathan Braun, Carolyn Cuff

Inflamm Bowel Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments.
Shelli Schomaker, David Potter, Roscoe Warner, Jane Larkindale, Nicholas King, Amy C Porter

PLoS One· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.
Mark D Stegall, Kenneth Troy Somerville, Matthew J Everly, Roslyn B Mannon, A Osama Gaber, Amy C Porter

Am J Transplant· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical biomarker qualification.
John-Michael Sauer, Amy C Porter,

Exp Biol Med (Maywood)· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 5th Annual One Mind Summit: Lessons Learned About "Science Informing Brain Health Policies and Practice".
Ramona Hicks, Stephen Johnson, Amy C Porter, Douglas Zatzick,

J Neurotrauma· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).
Xiaoshan Min, Stephen T Thibault, Amy C Porter, Darin J Gustin, Timothy J Carlson

Proc Natl Acad Sci U S A· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
Darin J Gustin, Zhihua Ma, Xiaoshan Min, Yihong Li, Christine Hedberg, Amy C Porter

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonoylethanolamine) concentration of rat brain.
Richard P Bazinet, Ho-Joo Lee, Christian C Felder, Amy C Porter, Stanley I Rapoport

Neurochem Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide.
Matthew J McFarland, Amy C Porter, Fariborz R Rakhshan, Diwan S Rawat, Richard A Gibbs

J Biol Chem· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-2 adrenergic receptors stimulate actin organization in developing fetal rat cardiac myocytes.
Amy C Porter, Samuel P S Svensson, W Daniel Stamer, Joseph J Bahl, Jeremy G Richman

Life Sci· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M1 muscarinic receptor signaling in mouse hippocampus and cortex.
Amy C Porter, Frank P Bymaster, Neil W DeLapp, Masahisa Yamada, Jürgen Wess

Brain Res· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Amy C Porter, John-Michael Sauer, Michael D Knierman, Gerald W Becker, Michael J Berna

J Pharmacol Exp Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis